Kenvue, Inc.: Hold Rating Amid Legal Uncertainties and Market Volatility
Citi analyst Filippo Falorni maintains a Hold rating on Kenvue, Inc. with a price target of $18.00, citing legal uncertainties from the MDL case on acetaminophen affecting stock performance. Recent court hearings favoring plaintiffs led to a drop in KVUE's stock price. Barclays also maintains a Hold rating with the same price target, reflecting cautious investor sentiment amid ongoing legal proceedings.
Citi analyst Filippo Falorni maintained a Hold rating on Kenvue, Inc. yesterday and set a price target of $18.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Filippo Falorni has given his Hold rating due to a combination of factors surrounding Kenvue, Inc. One of the primary reasons is the ongoing legal proceedings related to the MDL case on acetaminophen, which could potentially impact the company’s stock performance. The recent court hearing seemed to favor the plaintiffs, leading to a negative market reaction and a drop in KVUE’s stock price.
Furthermore, the uncertainty regarding the timeline for the court’s decision adds to the cautious outlook. Appeals courts typically take several months to deliver their opinions, which means this legal issue could continue to affect Kenvue’s stock in the near future. Despite these challenges, the expected share price return remains at 10.8%, which supports the Hold rating as investors await further clarity on the legal front.
In another report released on November 7, Barclays also maintained a Hold rating on the stock with a $18.00 price target.
